Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2-Reference-Cited by-同舟云学术

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2

Published:2016-11-07 Issue:49 Volume:7 Page:81555-81570
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Riva Beatrice¹,Dominici Marco De²,Gnemmi Ilaria¹,Mariani Samanta A.³,Minassi Alberto¹,Minieri Valentina²,Salomoni Paolo⁴,Canonico Pier Luigi¹,Genazzani Armando A.¹,Calabretta Bruno²,Condorelli Fabrizio¹

Affiliation:

1. Department of Pharmacological Sciences, Università del Piemonte Orientale “A. Avogadro”, 28100 Novara, Italy

2. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia 19107, PA, USA

3. MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, UK

4. Samantha Dickson Brain Cancer Unit, University College London Cancer Institute, London WC1E 6BT, UK

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers;Medical Oncology;2024-01-02

2. Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies;Frontiers in Nutrition;2022-10-26

3. Cadherins, Selectins, and Integrins in CAM-DR in Leukemia;Frontiers in Oncology;2020-12-10

4. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement;Biomedicine & Pharmacotherapy;2020-09

5. Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells;Scientific Reports;2020-03-16